CIAM
CCCC icon

Caitong International Asset Management’s C4 Therapeutics CCCC Stock Holding History

Caitong International Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3K Buy
3,698
+3,106
+525% +$10.6K ﹤0.01% 1025
2026
Q1 		$1.56K Buy
+592
New +$1.39K ﹤0.01% 1295
2025
Q4 		– Sell
-19,146
Closed -$42.5K – 1932
2025
Q3 		$42.5K Buy
+19,146
New +$46K 0.03% 375
2025
Q1 		– Sell
-15
Closed -$54 – 2202
2024
Q4 		$54 Buy
+15
New +$75 ﹤0.01% 1640

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Caitong International Asset Management's CCCC Position: Q2 2026 in Review

Caitong International Asset Management increased its C4 Therapeutics (CCCC) stake by 525% in Q2 2026, buying an estimated $10.6K and bringing the position to 3,698 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1025.

Caitong International Asset Management first reported a position in CCCC in Q4 2024 and has held it in 4 quarters since. The position peaked at $42.5K in Q3 2025. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Caitong International Asset Management held 3,698 shares of C4 Therapeutics worth $17.3K as of Q2 2026.
  • Caitong International Asset Management bought 3,106 C4 Therapeutics shares in Q2 2026, an estimated $10.6K.
  • C4 Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1025 holding.
  • Caitong International Asset Management first reported a position in C4 Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Caitong International Asset Management's C4 Therapeutics position peaked at $42.5K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.